Showing 1-10 of about 48 articles.
Questcor Pharmaceuticals
Questcor Appoints Jason Zielonka, M.D. Chief Medical Officer
UNION CITY, Calif., Feb. 4, 2010 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that Jason Zielonka, M.D., (61), has been appointed to the position of Chief Medical Officer. Dr. Zielonka has accepted the Company's offer to become Chief Medical Officer effective February 16, 2010 and will report directly to Don M. Bailey, President & Chief Executive Officer. He will lead Questcor's Medical Affairs organization and related initiatives and is taking over these responsibilities from Steve Cartt (47), Executive Vice President, who has been leading the company's Medical Affairs efforts since the function was created at Questcor in late 2007. In connection with this change, Steve Cartt has assumed the new title of Executive Vice President & Chief Business Officer.
Questcor Pharmaceuticals
Louis Silverman Appointed to Questcor Board of Directors
UNION CITY, Calif., Dec. 11, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that Louis E. Silverman has been appointed to its Board of Directors. Mr. Silverman, 51 is currently Chief Executive Officer of privately-held Marina Medical Billing Service Inc. based in Cerritos, CA, a company focused on providing revenue cycle management services to emergency room physicians nationally.
Questcor Pharmaceuticals
Questcor Announces Third Quarter 2009 Results
UNION CITY, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today reported financial results for its third quarter ended September 30, 2009. As previously reported on September 21, 2009, Questcor's financial results were negatively affected by the combination of a lower number of shipped and paid prescriptions for the treatment of infantile spasms (IS) and unusually high amounts of Medicaid rebates related to older Acthar usage. These factors were partially offset by the continued sequential improvement in sales of Acthar in the multiple sclerosis (MS) market.
Questcor Pharmaceuticals
Questcor Issues Corrected Dial-in Numbers for November 2nd Quarterly Conference Call
UNION CITY, Calif., Oct. 26, 2009 (GLOBE NEWSWIRE) -- In the news release, "Questcor Announces Third Quarter 2009 Earnings Release Date and Conference Call," issued on October 23, 2009 by Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR), the conference call dial-in numbers for domestic and international participants were transposed. Questcor will release financial results for the third quarter ended September 30, 2009 on Monday, November 2, 2009 after the market close. The Company will host a conference call and webcast on Monday, November 2, 2009 at 4:30 p.m. Eastern/1:30 p.m. Pacific to discuss the Company's third quarter and current corporate developments. The dial-in number for the conference call is 877-941-2332 for domestic participants and 480-629-9723 for international participants.
Questcor Pharmaceuticals
Questcor Announces Third Quarter 2009 Earnings Release Date and Conference Call
UNION CITY, Calif., Oct. 23, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that it will release financial results for the third quarter ended September 30, 2009 on Monday, November 2, 2009 after the market close. The Company will host a conference call and webcast on Monday, November 2, 2009 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's second quarter and current corporate developments. The dial-in number for the conference call is 480-629-9723 for domestic participants and 877-941-2332 for international participants.
Questcor Pharmaceuticals
Questcor Implements Two Corporate Governance Actions
UNION CITY, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that its Board of Directors has unanimously approved two corporate governance matters to provide Questcor's shareholders more say with respect to proposals to acquire the Company and better information about the economic interests of proponents of shareholder proposals and director nominations.
Questcor Pharmaceuticals
Questcor Expands Management Team
UNION CITY, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that David Young, Pharm.D., Ph.D., currently a member of Questcor's Board of Directors, has been appointed to the newly created position of Chief Scientific Officer, and Sian E. Bigora, Pharm.D. has been appointed to the newly created position of Vice President Regulatory Affairs. Dr. Young (56) joins Questcor from AGI Therapeutics plc where he served as Executive Director & President, U.S. Operations for the specialty pharmaceutical company since 2006. Dr. Bigora also joins Questcor from AGI Therapeutics where she served as Vice President, Clinical Research and Regulatory Affairs since 2007. Both executives will be based in Questcor's new East Coast offices in Columbia, Maryland. Dr. Young will resign from Questcor's board effective on his start date as an employee of the Company.
Showing 1-10 of about 48 articles.